Medtronic PLC $MDT Shares Sold by Handelsbanken Fonder AB

Handelsbanken Fonder AB cut its holdings in Medtronic PLC (NYSE:MDT) by 1.1% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 596,254 shares of the medical technology company’s stock after selling 6,509 shares during the quarter. Handelsbanken Fonder AB’s holdings in Medtronic were worth $46,645,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. New England Capital Financial Advisors LLC grew its stake in shares of Medtronic by 7.8% during the 4th quarter. New England Capital Financial Advisors LLC now owns 1,403 shares of the medical technology company’s stock worth $135,000 after purchasing an additional 101 shares during the period. Ipsen Advisor Group LLC lifted its stake in shares of Medtronic by 1.7% in the fourth quarter. Ipsen Advisor Group LLC now owns 5,952 shares of the medical technology company’s stock valued at $572,000 after purchasing an additional 101 shares during the period. Quadrant Capital Group LLC lifted its stake in shares of Medtronic by 0.3% in the fourth quarter. Quadrant Capital Group LLC now owns 32,477 shares of the medical technology company’s stock valued at $3,120,000 after purchasing an additional 101 shares during the period. Rossby Financial LCC lifted its stake in shares of Medtronic by 5.1% in the fourth quarter. Rossby Financial LCC now owns 2,193 shares of the medical technology company’s stock valued at $211,000 after purchasing an additional 107 shares during the period. Finally, Wealthspire Retirement LLC boosted its holdings in Medtronic by 5.0% during the fourth quarter. Wealthspire Retirement LLC now owns 2,410 shares of the medical technology company’s stock worth $232,000 after buying an additional 114 shares in the last quarter. Institutional investors and hedge funds own 82.06% of the company’s stock.

Medtronic Stock Performance

NYSE:MDT opened at $90.55 on Wednesday. The company has a current ratio of 2.13, a quick ratio of 1.62 and a debt-to-equity ratio of 0.52. The firm has a 50-day moving average price of $82.59 and a two-hundred day moving average price of $86.48. Medtronic PLC has a twelve month low of $73.31 and a twelve month high of $106.33. The company has a market capitalization of $115.91 billion, a P/E ratio of 24.28, a price-to-earnings-growth ratio of 2.40 and a beta of 0.55.

Medtronic (NYSE:MDT) last announced its quarterly earnings results on Wednesday, June 3rd. The medical technology company reported $1.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.54 by $0.01. The company had revenue of $9.81 billion for the quarter, compared to the consensus estimate of $9.62 billion. Medtronic had a net margin of 13.20% and a return on equity of 14.51%. The company’s revenue for the quarter was up 9.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.62 earnings per share. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. As a group, research analysts expect that Medtronic PLC will post 5.94 earnings per share for the current fiscal year.

Medtronic Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, July 17th. Investors of record on Friday, June 26th were paid a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a yield of 3.2%. The ex-dividend date of this dividend was Friday, June 26th. This is an increase from Medtronic’s previous quarterly dividend of $0.71. Medtronic’s dividend payout ratio is currently 77.21%.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the stock. Needham & Company LLC restated a “buy” rating and set a $101.00 target price on shares of Medtronic in a research report on Wednesday, June 17th. The Goldman Sachs Group reduced their price target on shares of Medtronic from $84.00 to $83.00 and set a “neutral” rating for the company in a research report on Thursday, June 4th. JPMorgan Chase & Co. decreased their price target on Medtronic from $100.00 to $86.00 and set a “neutral” rating on the stock in a research note on Thursday, June 4th. Mizuho dropped their price objective on Medtronic from $120.00 to $100.00 and set an “outperform” rating for the company in a research note on Wednesday, June 3rd. Finally, Wall Street Zen raised Medtronic from a “hold” rating to a “buy” rating in a research note on Saturday, July 18th. Eighteen equities research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $98.83.

Insider Transactions at Medtronic

In other Medtronic news, EVP Harry Skip Kiil sold 4,189 shares of the stock in a transaction on Monday, June 8th. The stock was sold at an average price of $80.44, for a total transaction of $336,963.16. Following the sale, the executive vice president owned 37,227 shares in the company, valued at approximately $2,994,539.88. This represents a 10.11% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.26% of the company’s stock.

Trending Headlines about Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Analyst upgrades reinforce the turnaround thesis. UBS upgraded Medtronic to Buy from Neutral, citing evidence that a turnaround is underway. Additional analyst upgrades point to the company’s strongest annual revenue growth in roughly a decade, driven by its cardiac portfolio and new product launches. Medtronic Wins Analyst Upgrades, Is It Fully Priced?
• Positive Sentiment: Options activity signals increased bullish interest. Investors purchased 19,654 MDT call options, 56% above typical daily call volume. While this is speculative rather than a fundamental measure, it suggests rising short-term trader interest.
• Positive Sentiment: Growth opportunities remain substantial in cardiac care. A new industry report projects the global pulsed-field ablation market to grow from approximately $3.2 billion in 2026 to $14.6 billion by 2035. Medtronic is listed among the major competitors that could benefit from expanding adoption of the technology. Pulsed Field Ablation Global Market Report 2026
• Positive Sentiment: Pipeline collaboration is progressing. Orchestra BioMed said its BACKBEAT pivotal trial, conducted with Medtronic, remains on track to reach its enrollment target by the end of the third quarter, with primary data expected in the second quarter of 2027. Successful results could create an additional future growth driver. Orchestra BioMed Reports Second Quarter Results
• Neutral Sentiment: Valuation is becoming a key investor question. After its recent advance, investors are assessing whether Medtronic’s improving outlook is already reflected in the share price. The company’s forward growth, dividend support and FY2027 EPS guidance of $5.90–$6.00 provide fundamental support, but continued gains may require evidence that the recovery is sustainable.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).